sellWeak cluster of 4
Carl DeLuca sold $397 of LICY
See Remarks at Li-Cycle Holdings Corp.. 391 shares at an average of $1.02, traded Jan 31, 2025, filed Feb 4, 2025.
Warning score
30Value
$397
391 shares
Holdings after
100,441
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$397 at market
- 0Share of holdings soldSold 0.4% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-013933, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | SOpen-market sale Common Shares | -391 | $1.02 | $397 | 100,441 | Feb 4, 2025 |
Related signals
Other insiders at Li-Cycle Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Li-Cycle Holdings Corp. | Ajay Kochhar President and CEO | $1,285 1,266 shares | -1% | |
| 30Weak | Li-Cycle Holdings Corp. | Christopher J. Biederman Chief Technology Officer | $331 326 shares | -0% | |
| 40Moderate | Li-Cycle Holdings Corp. | Ajay Kochhar President and CEO | $3,448 3,207 shares | -2% | |
| 30Weak | Li-Cycle Holdings Corp. | Christine Barwell Chief Human Resources Officer | $1,533 1,426 shares | -2% | |
| 30Weak | Li-Cycle Holdings Corp. | Christopher J. Biederman Chief Technology Officer | $565 526 shares | -1% | |
| 30Weak | Li-Cycle Holdings Corp. | Carl DeLuca See Remarks | $903 840 shares | -1% | |
| 20Weak | LICYsell Li-Cycle Holdings Corp. | Conor Spollen Chief Operating Officer | $9,379 4,970 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.